Regeneron Pharmaceuticals, Inc. v Sandoz Pty Ltd

Link copied
Case Copied 70 min read

FEDERAL COURT OF AUSTRALIA

Regeneron Pharmaceuticals, Inc. v Sandoz Pty Ltd [2025] FCA 1067

File number: VID 715 of 2025
Judgment of: ROFE J
Date of judgment: 3 September 2025
Catchwords:

PRACTICE AND PROCEDURE – patents – interlocutory injunction application – prima facie case – infringement – validity of patents – balance of convenience – application refused

PATENTS – aflibercept – VEGF Antagonist – claim construction – infringement – infringing and non-infringing uses – novelty – inventive step – support

Legislation:

Australian Consumer Law (Schedule 2 to the Competition and Consumer Act 2010 (Cth))

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

National Health Act 1953 (Cth), ss 85AB, 85AD(1), 85C

Patents Act 1990 (Cth), ss 7, 13, 18, 40(3), 117(1), 117(2)(b), 117(2)(c)

Therapeutic Goods Act1989 (Cth), s 23B(2)(e)

Cases cited:

Allied Pumps Pty Ltd v LAA Industries Pty Ltd (2023) 179 IPR 1

Apotex Pty Ltd v Cipla Ltd [2017] FCA 1627

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 304 ALR 1

AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324

AstraZeneca AB v Apotex Pty Ltd (2015) 323 ALR 605

Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57

Beadcrete Pty Ltd v Fe Yu (t/as Jewels 4 Pools) (No 3) (2013) 100 IPR 188

Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618

Décor Corporation Pty Ltd v Dart Industries Inc (1988) 13 IPR 385

Fei Yu (t/as Jewels 4 Pools) v Beadcrete Pty Ltd (2014) 107 IPR 516

Flexible Steel Lacing Co v Beltreco Ltd (2000) 49 IPR 331

General Tire and Rubber Co v Firestone Tyre and Rubber Co Ltd (1971) 1A IPR 121

Generic Health Pty Ltd v Otsuka Pharmaceutical Co Ltd (2013) 296 ALR 50

Glass Hardware v TCT Group Pty Ltd (2024) 182 IPR 1

Hood v Bush Pharmacy Pty Ltd (2020) 158 IPR 229

Interpharma Pty Ltd v Hospira Inc (No 5) (2019) 149 IPR 182

Jupiters Ltd v Neurizon Pty Ltd (2005) 65 IPR 86

Kirin-Amgen Inc v Hoechst Marion Roussel Ltd (2004) 64 IPR 444

Miele & Cie KG v Bruckbauer [2025] FCA 537

Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd (2020) 279 FCR 354

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd (No 5) [2024] FCA 360

Novozymes A/S  v Danisco A/S (2013) 99 IPR 417

Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (2012) 291 ALR 763

Pharmacia Italia SpA & Anor v Interpharma Pty Ltd (2005) 67 IPR 397

Product Management Group Pty Ltd v Blue Gentian LLC (2015) 116 IPR 54

Samsung Electronics Co Ltd v Apple Inc (2011) 217 FCR 238

Sandoz AG v Bayer Intellectual Property GmbH (2024) 183 IPR 309

Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (2019) 139 IPR 409

Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) (2018) 138 IPR 242

ToolGen Incorporated v Fished (No 2) [2023] FCA 794

Tramanco Pty Ltd v BPW Transpec Pty Ltd (2014) 105 IPR 18

Warner-Lambert Co LLC…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Regeneron Pharmaceuticals, Inc. v Sandoz Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] FCA 1067
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, Regeneron Pharmaceuticals, Inc., along with its affiliates, sought an interlocutory injunction against Sandoz Pty Ltd, aiming to prevent the latter from launching a biosimilar version of aflibercept, a VEGF antagonist used in the treatment of various ocular conditions. The primary legal issues were whether Regeneron had established a prima facie case for patent infringement, the validity of the patents in question, and the balance of convenience favouring the grant of interim relief. The court was tasked with determining if the potential harm to Regeneron outweighed the prejudice to Sandoz if the injunction were granted.

The court found that Regeneron had not demonstrated a strong likelihood of success on the merits of their infringement claims, as the construction of the patent claims was not sufficiently clear to conclude that Sandoz's product would infringe. Additionally, the validity of the patents was challenged on grounds of novelty and inventive step, which the court considered to be contentious issues that would likely be resolved in Sandoz's favour. Regarding the balance of convenience, the court noted that the appeal process would significantly delay any final determination, diminishing any advantage Regeneron might have as a first mover in the market. Consequently, the court determined that the balance of convenience did not favour granting the interim relief sought by Regeneron.

The court dismissed Regeneron's application for interlocutory injunctive relief. The reasons for the judgment were to be kept confidential, with the parties to propose redactions for sensitive information. If the parties could not agree on the redactions, they were to list their respective proposals. Costs were reserved pending further directions.

Orders

Orders of the court

1. The Applicants’/ Cross Respondents’ claim for interlocutory relief in paragraphs 11 to 14 of its Amended Originating Application dated 8 August 2025 be dismissed.

2. Until further order, the Court’s reasons for judgment not be disclosed to or published by any person, save for the parties’ legal representatives and Court staff.

3. Within fourteen days, the parties confer, prepare and provide to the Chambers of Justice Rofe, proposed redactions to the reasons for judgment in relation to paragraphs that contain confidential information.

4. If the parties are unable to agree on the proposed redactions referred to in order 3, each of the parties should file and serve on or before 29 September 2025:

(a) a list of paragraphs of the agreed redactions; and

(b) a list of paragraphs each of the parties consider ought to be redacted.

5. Costs be reserved.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Factoring in an appeal, Sandoz did not consider that there would be final determination of the proceeding in a timeframe that left it with any advantage (i.e., first mover advantage) over other potential biosimilar competitors.1.4 Summary of conclusion For the reasons I set out below, I consider that the balance of convenience does not lie in favour of the grant of interim relief sought by the Applicants. Accordingly, I dismiss the interlocutory application for injunctive relief. 1.5 The witnesses The Applicants rely on evidence from seven witnesses:·Mark Davies Daniell is a senior consultant ophthalmologist at the Royal Victorian Eye and Ear Hospital (RVEEH) and Clinical Professor (Prof) of Ophthalmology at the Centre for Eye Research, University of Melbourne. Prof Daniell is the immediate past president of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and has held numerous professional memberships and positions in societies, councils and authorities. Prof Daniell obtained a MBBS and Master of Surgery degrees from the University of Melbourne in 1986 and 1992, respectively. Prof Daniell gives evidence on the treatment of neovascular AMD and diabetic macular oedema (DME) using intravitreal injections of VEGF antagonist, and how the landscape for the treatment of those conditions will change if a biosimilar to one of the anti-VEGF reference drugs became available in Australia. The Applicants rely on one affidavit affirmed by Prof Daniell. ·Robert Charles Andrew Symons is an Ophthalmologist, Vitreoretinal Surgeon and Clinician Scientist at the Centre for Eye Research Australia, the University of Melbourne and Monash University, with over 30 years’ experience working as a clinician in the field of ophthalmology and with particular expertise in the treatment of retinal disorders. Associate Professor (A/Prof) Symons has been appointed as an Investigator or Trial Committee Member of a number of ophthalmological Phase I, II and III clinical trials. The Applicants rely on one affidavit affirmed by A/Prof Symons.·Jan Gritzmann is the Senior Director, Finance and Administration of Regeneron Ireland Designated Activity Company, a wholly owned subsidiary of Regeneron. Mr Gritzmann provides evidence on the relationship between the Applicants, and potential losses, particularly to Regeneron, if the Sandoz Aflibercept Products were launched in Australia. The Applicants rely on one affidavit affirmed by Mr Gritzmann.·James Thomas Rock is the Marketing Strategic Lead of Ophthalmology and Oncology at Bayer Australia. Based on his experience as an employee of Bayer Australia and his oversight of the commercial operation of the EYLEA® brand, Mr Rock leads evidence on the existing market of anti-VEGF drugs, the contractual business relationships between the Applicants, the internal arrangements between Bayer Australia and Bayer Consumer Care, and the purported loss and damage which may arise should a biosimilar be launched into the Australian anti-VEGF drug market. The Applicants rely on one affidavit affirmed by Mr Rock.·Suyuan Zha is a Certified Practising Accountant and the Pricing & Reimbursement Manager of Bayer Australia. Ms Zha gives evidence to the regulatory history of EYLEA®, the operation of the PBS as it relates to EYLEA® and any biosimilar versions, and the impact on the pricing of EYLEA® and other anti-VEGF drugs should Sandoz obtain PBS listing for the Sandoz Aflibercept Products. The Applicants rely on one affidavit affirmed by Ms Zha.·Grant William Fisher is a Partner at Corrs Chambers Westgarth, the solicitors representing Regeneron. Mr Fisher gives evidence on the amino acid sequences in Australian Patents Nos 2006229930, 779303 and 2006213856 (the 856 Patent). Mr Fisher gives further evidence on the correspondence between the parties regarding the process whereby the 599 Patent and the 856 Patent were selected as patents asserted and to be asserted against Sandoz. The Applicants rely on three affidavits affirmed by Mr Fisher, one of them being relevant to the present interlocutory injunctive relief case. ·Owain Rhys Stone is a Managing Director of Alvarez & Marsal’s disputes and investigations practice in Melbourne, with over 40 years’ experience as a forensic accountant. Mr Stone gives evidence on his approach to the quantification of loss sustained by the parties in both launch and restraint scenarios. The Applicants rely on one affidavit affirmed by Mr Stone.

Ratio Decidendi

Legal Principle Established

The Sandoz PI provides the following in relation to Wet AMD and DME:The interval between doses injected into the same eye should not be shorter than one month.Advice on treatment initiation and maintenance of therapy specific to each patient population is described in the section below. Once optimal visual acuity is achieved and/or there are no signs of disease activity, treatment may then be continued with a treat-and-extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes. If disease activity persists or recurs, the treatment interval may be shortened accordingly. Monitoring should be done at injection visits. The monitoring and treatment schedule should be determined by the treating ophthalmologist based on the individual patient’s response. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, AFQLIR should be discontinued. • Treatment of neovascular (wet) age-related macular degeneration (wet AMD)AFQLIR 2 mg treatment is initiated with one AFQLIR 2 mg injection per month for three consecutive months, followed by one injection every two months.Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at two months or further extended using a treat-and-extend dosing regimen, by increasing injection intervals in 2- or 4-weekly increments while maintaining stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened to a minimum of four weeks based on anatomical and/or visual outcomes. […]• Treatment of diabetic macular oedema (DME)AFQLIR 2 mg treatment is initiated with one AFQLIR 2 mg injection per month for five consecutive months.Following the initiation period and based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may then be maintained at an injection every two months or further individualised, such as with a treat-and-extend dosing regimen, by increasing injection intervals in 2- or 4-weekly increments while maintaining stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. Treatment intervals shorter than 4 weeks or longer than 4 months have not been studied (see Section 5.1 Pharmacodynamic properties, Clinical trials). (Emphasis added in italics.) (Emphasis in original in bold.) In addition to Wet AMD and DME, the Sandoz PI also discusses treatment using the Sandoz Aflibercept Products for CRVO, BRVO and CNV.3.4.2Ophthalmologist treatment regimens for EYLEA® 2mg A/Prof Wickremasinghe currently uses EYLEA® 2mg as his standard treatment for both Wet AMD and DME. He uses what he describes as a “treat-and-extend” strategy which he considers to be the standard treatment strategy for Wet AMD in the Australian ophthalmology community. A/Prof Wickremasinghe notes that because the treatment of DME is less predictable, “a treat-and-extend strategy can be less useful in DME (although for some patients, it is appropriate)”.